All Oncology News

An NDA for rivoceranib plus camrelizumab in frontline HCC has been resubmitted to the FDA, following the company's receipt of 2 CRLs for this indication.

OncLive outlines some of the most notable new agents and combinations to earn FDA approval in 2025, including the topline data supporting these decisions.

IBI3003 received fast track designation from the regulatory agency in the setting of relapsed/refractory multiple myeloma.

The emergence of ultrasensitive ctDNA and CSF testing may help alter monitoring strategies and adaptive clinical trial designs in metastatic breast cancer.

Oncology Fellows spotlights fellows who received research fellowship grants during the 2025 ESMO Congress.

The clinical benefit and disease control rates were both 100% with lurbinectedin plus ipilimumab/nivolumab in patients with advanced soft tissue sarcoma.

Nicholas Polizzi, PhD, and Edward Boyden, PhD, are recipients of the December 2025 Medical Research Grant from the W. M. Keck Foundation.

The gremlin-1–directed monoclonal antibody ginisortamab showed early efficacy signals when combined with SOC therapy in patients with advanced GI tumors.

The FDA has approved a 375-mg vial of nelarabine for intravenous administration in both T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

Nuvisertib was well tolerated with no dose-limiting toxicities and promising efficacy in relapsed/refractory myelofibrosis.

The predictive value of PD-L1 expression on response to chemoimmunotherapy was greater on metastatic lesions vs primary tumors in HGSOC.

Andrew Yee, MD, and Krina Patel, MD, MSc, discuss up-and-coming oral PI combination regimens in relapsed/refractory multiple myeloma.

The FDA has approved daratumumab and hyaluronidase plus VRd for adult patients with newly diagnosed multiple myeloma who are not eligible for ASCT.

A meta-analysis found rapid progression and hyperprogression with nivolumab plus ipilimumab in renal medullary carcinoma.

Radiation therapy administered prior to surgery rarely shrinks retroperitoneal tumors in sarcoma according to Fox Chase Cancer Center researchers.

The novel oral fascin inhibitor NP-G2-044 received FDA orphan drug designation for patients with pancreatic cancer.

Andrew Yee, MD, and Krina Patel, MD, MSc, discuss updates to the NCCN guidelines and key data updates in relapsed/refractory multiple myeloma.

Guillermo Garcia-Manero, MD, discusses the phase 3 GLORA-4 study of lisaftoclax plus azacitidine in higher-risk MDS.

The resubmission of an sBLA of nogapendekin alfa inbakicept plus BCG in BCG-unresponsive, papillary-only NMIBC was discussed with the FDA.

Sagar Lonial, MD, FACP, FASCO, discusses findings from the CC-220-MM-001 trial of iberdomide plus daratumumab and dexamethasone in newly diagnosed myeloma.

A global analysis led by Dana-Farber combined patient data from 6 major clinical trials to compare 2 immunotherapies for advanced non–small cell lung cancer.

A SEER analysis showed that immune checkpoint inhibitors better improved OS for younger patients vs older patients with advanced renal cell carcinoma.

Raji Shameem, MD, discusses the continuing evolution of the frontline treatment landscape of metastatic pancreatic cancer.

Sara Tolaney, MD, MPH, discusses the recent FDA approval of T-DXd and pertuzumab for HER2-positive breast cancer and its supporting data.

Treatment with first-line metronomic cyclophosphamide did not significantly improve TTF, PFS, or OS vs doxorubicin in advanced soft tissue sarcoma.

The NCCN guidelines recognize that MammaPrint can help identify a subset of patients with early-stage breast cancer likely to benefit from anthracycline-based therapy.

WJ01024 alone and in combination with ruxolitinib was safe and generated efficacy signals in relapsed/refractory myelofibrosis.

Jonathan Lee, MD, MSc, offers his tips for interviewing for a hematology/oncology fellowship.

Gotistobart received orphan drug designation from the FDA for patients with squamous NSCLC.

Nogapendekin alfa inbakicept plus PD-L1 t-haNK and bevacizumab produced encouraging overall survival data in recurrent glioblastoma.